Diversifying acute leukemia trial enrollment through multilevel approach
Official title: Diversifying Acute Leukemia Clinical Trial Enrollment Through Multilevel Intervention
Funded at Dana-Farber Cancer Inst · NIH-11362223 · Data updated 2026-11-12
Aiming to broaden participation in acute leukemia trials by testing a multi-layer plan that addresses barriers for adults with AML.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | July 1, 2022 |
| Project end | June 30, 2027 |
| Funding year | 2026 |
| Award (this year) | $207,900 |
| NIH project number | 5K08CA273043-05 |
| Project ID | NIH-11362223 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults 21 and older with acute myeloid or lymphoblastic leukemia who may consider trial participation.
✕Less likely to help
People without acute leukemia or those not exploring trial options may not directly benefit.
What this research studies
This project looks at why adults with acute leukemia aren’t equally enrolled in cancer trials and how to fix it. Researchers will use data from cancer registries and electronic health records to spot enrollment barriers and test a three-part strategy. The plan includes a preemptive review system for trial design, community input, and tailored interventions to improve access and participation. If successful, the approach could make trials more representative and help patients receive cutting‑edge therapies sooner.
Why it matters
Potential benefit: If successful, patients with acute leukemia could access more trials and high-quality care.
How similar studies have gone: Previous work shows enrollment disparities; this project builds on data-driven methods to address them.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Hantel, Andrew — Dana-Farber Cancer Inst
- Study coordinator: Hantel, Andrew
Related research
Other NIH-funded projects on the same topics.
-
Investigating a specific type of leukemia in children caused by genetic changes.
This study is looking at how certain proteins linked to leukemia affect kids and teens with high-risk blood cancers, and the researchers hope to find new ways to treat these conditions by learning more about how the disease works.
-
Reducing leukemia disparities in Latino children and teens
A large, multi-project effort aims to understand why Latino children with acute lymphoblastic leukemia have worse outcomes and how to reduce those gaps.
-
Genomic advances to improve outcomes in high-risk acute leukemia
A physician-scientist team is studying the genetic drivers of pediatric acute leukemia to find new ways to diagnose and treat it, with the goal of improving cure rates for kids.
-
Understanding and Targeting Extramedullary Acute Leukemia
A clinician-research team is studying myeloid sarcoma, a form of AML that forms solid tumors outside the bone marrow, to develop new treatments for patients.
-
Blocking menin to treat acute leukemias with high HOX gene activity
This work develops new drugs that block a protein called menin to help people with certain aggressive acute leukemias driven by HOX gene activation.
-
Predicting methotrexate-related brain side effects in children with ALL
This project works to predict which children and teens with acute lymphoblastic leukemia will develop methotrexate-related neurotoxicity using clinical signs and biological data.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.